Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Antitumor Activity of JSKN021 in Advanced Malignant Solid Tumors

NCT07617727 is registered in ClinicalTrials.gov with Jiangsu Alphamab Biopharmaceuticals Co., Ltd as lead sponsor.

NCT NCT07617727
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07617727 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Antitumor Activity of JSKN021 in Advanced Malignant Solid Tumors
Lead sponsor
Jiangsu Alphamab Biopharmaceuticals Co., Ltd
Phase
Phase 1
Overall status
Recruiting
Start date
June 2, 2026
Completion date
May 31, 2029
Enrollment
199 (estimated)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

advanced malignant solid tumors